Meeting
2014 Genitourinary Cancers Symposium
Sequential monitoring and characterization of circulating tumor cells (CTCs) using the epic sciences platform in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) treated with recently approved therapeutics.
Authors
Roberta Ferraldeschi
The Institue of Cancer Research, The Royal Marsden NHS Foundation Trust, Sutton, United Kingdom
Roberta Ferraldeschi , Rachel Krupa , Jessica Louw , Eric Tucker , Natalee Bales , Dena Marrinucci , Penelope Flohr , Ines Figueiredo , David Lorente , Ryan Dittamore , Johann Sebastian De Bono , Gerhardt Attard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
General Poster Session A: Prostate Cancer
Track
Prostate Cancer
Sub Track
Prostate Cancer
Citation
J Clin Oncol 32, 2014 (suppl 4; abstr 78)
DOI
10.1200/jco.2014.32.4_suppl.78
Abstract #
78
Poster Bd #
E13
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
AR-V7 in Asian patients with metastatic CRPC: A multinational, multicentre study.
First Author: Hui Shan Tan
Poster
2020 ASCO Virtual Scientific Program
TALAPRO-1: Phase II study of talazoparib (TALA) in patients (pts) with DNA damage repair alterations (DDRm) and metastatic castration-resistant prostate cancer (mCRPC) – updated interim analysis (IA).
First Author: Johann S. De Bono
Poster
2020 Genitourinary Cancers Symposium
Circulating tumor cell (CTC) genomic signatures of hormone therapy resistance in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Santosh Gupta
Poster
2015 Genitourinary Cancers Symposium
AR splice variant 7 (AR-V7) and response to taxanes in men with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Emmanuel S. Antonarakis